← Leaderboards
Matthew James Spindler
Gigamune, Inc.
$1,455,000
Attributed
$1,455,000
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $800K · FY2018–23$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,455,000 · 4
By mechanism
R43$1,455,000 · 4
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Dna Sequencing”
- Leonard Freedman · Leidos Biomedical Research, Inc.$71,124,067
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$31,640,785
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,188,684
- Badri N Vardarajan · University Of Miami School Of Medicine$23,982,327
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
- Maria C Carrillo · Indiana University Indianapolis$19,445,642
Research focus
Dna SequencingNovel TherapeuticsSolid NeoplasmDoctor Of PhilosophyTechnologyTargeted TreatmentIn VitroSmall Business Innovation Research GrantT-LymphocyteGenesIn VivoLibrariesAntigensFda ApprovedAdoptive Cell TransfersEngineeringMicrofluidicsCellsEpitopesAllelesEffective TherapyBiotechnologyCatalogsClinical Trials
Grant awards (5)
Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens$55,000
R43 · FY2023 · AI · contact PI
Engineered TCR-Treg Cell Therapies Targeting Type 1 Diabetes Autoantigens$300,000
R43 · FY2022 · AI · contact PI
Engineered TCR-T Cell Therapy Targeting Driver Mutations in NSCLC$400,000
R43 · FY2021 · CA · contact PI
Engineered TCR-T Cell Therapies Targeting Shared Tumor Associated Antigens$400,000
R43 · FY2021 · CA · contact PI
Recombinant TIL Cell Therapy for Salvage Solid Tumor Patients$300,000
R43 · FY2018 · CA · contact PI